Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Articles

Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.

Eurofins Genomics Blue Heron Launches In-Vitro Transcription mRNA Synthesis Service 

Feliza Mirasol is the science editor for 

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene

Lei Lei is senior R&D director of Cutia Therapeutics, Shanghai, China, and he was principal scientist of Shanghai Johnson & Johnson Pharmaceutical Company

FDA’s new guidance on in-vitro permeation test studies published in October 2022 gives technical and statistical requirements for conducting these tests to compare topical generic drugs with their reference products.

In-Vitro Permeation Test Data Analysis with MS Excel as per FDA’s Guidance

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Sample dilution, sensitivity, excipient interference, and containment are key issues that must be addressed.

Overcoming Analytical Challenges in High Potency Formulation

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Aenova has opened a new building for the production of highly potent APIs in Germany.

Aenova Opens New Building for Highly Potent Drugs

Sandbox AQ’s molecular simulation division is collaborating with companies like AstraZeneca and Sanofi to develop novel treatments for various disorders.

SandboxAQ Launches Molecular Simulation Division

The new excipients manufacturing facility is expected to be completed in 2025.

Croda Pharma Breaks Ground on Excipients Manufacturing Facility

Webcasts

Webinar Date/Time: Tue, Jul 25, 2023 9:00 AM EDT

Post-COVID Supply Chains: Lockdown Lessons Learned

Emerging Trends in the Pharma Industry: Drug Development, Sustainability, and Digitalization

invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.